Journal articleEur J Cancer2024
A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.
- Journal
- Eur J Cancer
- Published
- 22 February 2024
- Citations
- 4
- Type
- Article
- License
- cc by-nc
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 1
- Its registry lists this paper as resultsStudy of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer NCT04953962↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.